Two RNA-binding proteins mediate the sorting of miR223 from

mitochondria into exosomes

Liang Ma[1], Jasleen Singh[1], and Randy Schekman[1] [*]

[1]Department of Molecular and Cell Biology, Howard Hughes Medical

Institute, University of California, Berkeley, United States.

[*]For correspondence: schekman@berkeley.edu

Abstract

Fusion of multivesicular bodies (MVBs) with the plasma membrane results in the secretion of intraluminal vesicles (ILVs), or exosomes. The sorting of one exosomal cargo RNA, miR223, is facilitated by the RNA-binding protein, YBX1 (Shurtleff et al., 2016). We found that miR223 specifically binds a "cold shock" domain (CSD) of YBX1 through a 5' proximal sequence motif UCAGU that may represent a binding site or structural feature required for sorting. Prior to sorting into exosomes, most of the cytoplasmic miR223 resides in mitochondria. An RNA-binding protein localized to the mitochondrial matrix, YBAP1, appears to serve as a negative regulator of miR223 enrichment into exosomes. miR223 levels decreased in the mitochondria and increased in exosomes after loss of YBAP1. We observed YBX1 shuttle between mitochondria and endosomes in live cells. YBX1 also partitions into P body granules in the cytoplasm (Liu et al., 2021). We propose a model in which miR223 and likely other miRNAs are stored in mitochondria and are then mobilized by YBX1 to cytoplasmic phase condensate granules for capture into invaginations in the endosome that give rise to exosomes.

Introduction

Extracellular vesicles (EVs) bud from the plasma membrane or are secreted when multivesicular bodies (MVB) fuse with the plasma membrane to release a population of vesicles called exosomes. EVs and their cargos are highly dependent on their membrane source. Microvesicles released by budding from the plasma membrane are a heterogeneous

population of EVs ranging in size from 30 nm to 1000 nm (Cocucci et al., 2009). Exosomes are 30 nm to 150 nm in size and originate as vesicles invaginated into the interior of an MVB to form intraluminal vesicles (ILVs) (Harding et al., 1983).

Many RNAs are selectively sorted into EVs, especially small RNAs. Several studies have indicated that RNA binding proteins (RNPs) may be involved in the enrichment of RNAs into EVs (Mukherjee et al., 2016; Santangelo et al., 2016; Teng et al., 2017; Villarroya-Beltri et al., 2013). However, many of these studies used sedimentation at ~100,000 g to collect EVs, which may also collect RNP particles not enclosed within membranes which complicates the interpretation of these data. To address this question, we previously developed buoyant density-based methods to separate EVs from non-vesicular aggregates and found that EVs form two distinct populations of high and low buoyant density (Shurtleff *et al.*, 2016; Temoche-Diaz et al., 2020) . We found that some miRNAs are selectively enriched in a high buoyant density vesicle fraction characterized by an enrichment in the exosomal marker protein CD63, whereas the low buoyant density EVs are fairly non-selective in the capture of miRNAs (Temoche-Diaz et al., 2019).   We developed a cell-free reaction to identify YBX1 as required for miR223 sorting into exosomes and demonstrated that it plays an important role in the enrichment of miR223 into exosomes in HEK293T cells (Shurtleff *et al.*, 2016). We subsequently found that phase separated YBX1 condensates selectively recruit miR223 *in vitro* and sort it into exosomes in cells (Liu *et al.*, 2021). In this study we report that YBX1 directly and specifically binds miR223 by its "cold shock" domain (CSD). We have identified a sequence motif, UCAGU, that facilitates the sorting of

miR223 into exosomes. We also found a significant fraction of cytoplasmic
miR223 localized within mitochondria, tightly associated with the
mitochondrial envelope and that a mitochondrial RNA-binding protein,
YBAP1, may control the transfer of miR223 from mitochondria to exosomes.

Results

YBX1 directly and specifically binds miR223

We previously documented that YBX1 facilitates miR223 sorting into
exosomes (Shurtleff *et al.*, 2016) and that exosomal miR223 is decreased
in YBX1 knockout cells (Liu *et al.*, 2021). We reexamined the enrichment
and confirmed that exosomal miR223 was decreased in exosomes purified
from YBX1 KO cells (Figure 1a). We used a Nanosight particle tracking
device to quantify buoyant density purified vesicles and found that knockout
of YBX1 did not affect exosome secretion (Figure 1 supplement 1).

Whereas the importance of YBX1 for miR223 sorting has been established,
the mechanism of their interaction was not known. To examine the direct
interaction of YBX1 and miR223, we used an electrophoretic mobility shift
assay (EMSA) with purified recombinant YBX1, expressed in insect cells
(Figure 1 supplement 2a), and chemically synthetic miR223 and miR190, a
cytoplasmic miRNA that is not enriched in exosomes. Purified YBX1 was
titrated and incubated with 5' fluorescently labeled miR223 at 30℃ for
30min. miR223-YBX1 complexes were separated by electrophoresis and
detected by in-gel fluorescence. The EMSA data showed that YBX1 directly
and specifically bound to miR223, but ~140-fold less well with miR190
(Figure 1b-c). The measured Kd for YBX1:miR223 was 4.2nM (Figure 1d).

YBX1 has three major domains including an N-terminal alanine/proline-rich

(A/P) domain, a central cold shock domain (CSD) and a C-terminal domain

(CTD) (Figure 1e). To explore which specific domain of YBX1 binds

miR223, we constructed a series of fragments: the A/P domain, CSD and

CTD. The YBX1 fragments were expressed in and purified from insect cells

(Figure 1 supplement 2b). EMSA data showed that the A/P domain and

CTD had little or no affinity for miR223, whereas the CSD domain bound

miR223 but with an affinity much reduced compared to full length YBX1

(Figure 1f). We then constructed two combined fragments of the A/P and

CSD and CSD and CTD domains (Figure 1 supplement 2c). The EMSA

data showed that the A/P domain was dispensable whereas binding of

miR223 to CSD plus CTD was comparable to full length YBX1 (Figure 1g).

YBX1-F85A in the CSD domain was reported to block the YBX1-specific

binding of mRNA (Lyons et al., 2016). Purified YBX1-F85A protein failed to

bind miR223 (Figure 1g, Figure 1 supplement 2c). These data suggest that

YBX1 directly and specifically binds miR223 via the CSD. The CTD of

YBX1 did not appear to bind miR223 but may somehow facilitate a higher

affinity interaction of the CSD with miR223.

A binding or structural motif on miR223 that promotes interaction

with YBX1 and enrichment into exosomes

We next sought to determine the miR223 sequence motif responsible for

interaction with YBX1 and enrichment into exosomes. We used an EMSA

competition assay with a series of miR223 mutants. Purified YBX1 and 5'

fluorescently labeled miR223 were incubated with miR223 mutant

constructs titrated in a range from 1nM to 1µM. miR223 variants in a

binding domain should not compete for interaction of YBX1 with 5'

fluorescently tagged miR223 whereas variations in sequences irrelevant to

interaction would compete. Using this EMSA competition assay to screen

the miR223 binding motif, we found that the competitive binding of

miR223mut (3-6) and miR223mut (4-7) were decreased (Figure 2

supplement 1). This suggested that the sequence UCAGU was critical for

interaction with YBX1. To test this directly, we employed a variant

sequence, termed miR223mut, where the UCAGU was substituted with

AGACA. As a positive control, we employed a variant of miR190,

miR190sort, where the sequence AUAUG was substituted with UCAGU

(Figure 2a). EMSA data showed a ~27-fold reduced YBX1 interaction of

with miR223mut whereas the affinity of miR190sort with YBX1 was

increased ~8 fold compared to wt sequences.

To test whether this motif is critical for miR223 enrichment into exosomes,

we purified exosomes from 293T cells transiently transfected to

overexpress one of the four miRNA constructs (Figure 2d). RT-qPCR data

showed that the level of miR223 in exosomes was ~ 4-fold dependent on

the putative exosomal sorting motif (Figure 3e) and the enrichment of

miR190sort into exosomes was increased ~5-fold compared to miR190 WT

(Figure 2f).

In previous work, we developed a cell-free reaction to test the biochemical

requirement for YBX1 in the sorting of miR223 into vesicles formed with

membranes and cytosol isolated from broken HEK293 cells (Shurtleff et al.

2016). In this work we showed that the sorting of miR223 and of a CD63-

luciferase fusion protein into an enclosed membrane were coincidentally

inhibited by GW4869 an inhibitor of neutral sphingomyelinase (NS2) known

to interfere with exosome biogenesis and secretion. On this basis, we

concluded that the cell-free reaction recapitulated the sorting event leading
to the packaging of miR223 into exosomes.

We refined this assay to measure the incorporation of ^{32}P-5' end-labeled wt
and mutant miR223 into vesicles formed *in vitro*. Isolated membranes and
cytosol were incubated with ^{32}P-labled wt or mutant miR223 at 30 °C for
20min, after which RNase I was added to digest any unpackaged miRNA.
Controls including 1% Triton X-100 were used to measure background
RNase resistant radiolabel. Samples were resolved on a gel for visual and
quantitative evaluation of membrane sequestered RNA (Figure 2g and 2h).
The results suggested that the UCAGU motif is critical for miR223
packaging into vesicles in the cell-free reaction.

Taken together the results in Fig. 2 show that the miR223 sequence
UCAGA promotes the binding of YBX1 in order to sort the miRNA into
vesicles formed in cells and in a cell-free reaction. We suggest this sorting
facilitates the export of miR223 in exosomes secreted from HEK293 cells.

Mitochondria contribute to miR223 enrichment into exosomes.

In a recent study we showed that YBX1 is sorted into P-bodies in cells and
that these biomolecular condensates may initiate the sorting of miR223 into
vesicles budding into the interior of endosomes (Liu *et al.*, 2021; Shurtleff *et*
al., 2016). Mitochondria represent another apparent intracellular location of
miR223 (Wang et al., 2020). We used cell fractionation of homogenates of
HEK293 cells to evaluate the subcellular distribution of endogenous
miR223. Fractionation was evaluated by immunoblot using marker proteins
characteristic of various cell organelles (Figure 3a). Analysis of RNA
extracted from isolated membranous organelles confirmed that miR223 but

not miR190 was significantly enriched in mitochondria but not in ER or

cytosol (Figure 3b, Figure 3 supplement 1a) (Wang *et al.*, 2020).

To determine the localization of miR223 on or within mitochondria, we

prepared mitoplasts using digitonin to strip away the mitochondrial outer

membrane followed by fractionation on a Percoll density gradient.

Immunoblots of the enriched mitochondria and isolated mitoplasts showed

that the outer membrane, marked by Tom20, was largely removed with

retention of the inner membrane marker Tim23 (Figure 3c). RNA was

extracted from the purified mitoplast and RT-qPCR data indicated that

miR223 was enriched along with mRNA for COX1, but not with nuclear U6

snRNA (Figure 3d).

As an independent means to assess the localization of cytoplasmic miR223,

we used immunoprecipitation to purify mitochondria. Isolated mitochondria

were then converted to mitoplasts by osmotic shock and treated with

proteinase K and RNase. Immunoblots of the immunoprecipitated

mitochondria and isolated mitoplasts showed that the outer membrane,

marked by Tom20, and intermembrane space, marked by AIF, were largely

removed with retention of the mitochondrial matrix marker citrate synthase

(Figure 3e). RNA was extracted from the immunoprecipitated mitochondria

and mitoplasts and RT-qPCR data indicated that miR223 was enriched

along with mRNA for COX1, but not with miR190 or nuclear U6 snRNA

(Figure 3f).

We also used immunoprecipitated mitochondria (Figure 3 supplement 1b)

and either Triton X-100 to solubilize the membrane or freeze-thaw to allow

the matrix and envelope fractions to be separated by centrifugation.

Mitochondrial membrane proteins, such as Tom20 and COX IV, were

solubilized and retained in the supernatant fraction (Figure 3 supplement

1c). The freeze-thaw regimen released citrate synthase to a supernatant

fraction whereas Tom20 and COX IV sedimented in the pellet fraction. RNA

was extracted from the detergent supernatant and pellet fractions where we

found similar distributions of COX1 and miR223, neither of which were as

readily solubilized as the inner and outer membrane proteins (Figure 3

supplement 1d). RT-qPCR quantification of fractions from the freeze-thaw

regimen showed that both COX1 mRNA and miR223 remained largely

associated with the sedimentable membrane fraction (Figure 3 supplement

1e). We conclude that miR223 is enclosed within mitochondria, possibly in

association with the inner membrane.

We sought a test of the role of mitochondria in the secretion of miR223 in

exosomes. For this purpose, we generated cells depleted of mitochondria

(Correia-Melo et al., 2017). U-2 OS cells expressing GFP-parkin were

treated with CCCP for 48h, conditions that cause mitochondria to be

removed by mitophagy. We confirmed mitochondrial depletion after CCCP

treatment by RT-qPCR of mitochondrial COX1 mRNA (Figure 3g) and

immunoblot of the mitochondrial inner membrane marker Tim23 (Figure 3h).

We then compared the levels of both miR223 and miR190 from GFP-parkin

expressing U-2 OS cells with and without CCCP treatment. RT-qPCR data

showed that miR223, but not miR190, increased 3-fold in cells treated with

CCCP (Figure 3j). To test the possibility that miR223 accumulated in cells

as a result of a failure of mobilization into exosomes, we compared the

miR223 levels in exosomes purified from untreated and CCCP treated cells

(Fig. 3 j). Although exosome secretion, as measured with a CD63-

luciferase marker, did not change after CCCP treatment (Figure 3

supplement 2a), we found that CCCP treatment lowered the amount of

miR223 in EVs 4-fold (Figure 3j). The increase in cellular at the expense of

exosomal miR223 may reflect a critical role for mitochondria in the

mobilization of this RNA to exosomes.

YBAP1 binds miR223 in the mitochondria and in vitro.

In the course of purifying a tagged version of YBX1 from 293T cells, we

observed another protein that copurified and found that it corresponded to

YBAP1 (Figure 4a, b). Such a complex of YBX1 and YBAP1 has previously

been reported (Matsumoto et al., 2005). We confirmed that purified YBX1

and YBAP1 bind each other by coexpression and affinity purification from

insect cells (Figure 4 supplement 1b). YBAP1 is a mitochondrial matrix

protein with a standard N-terminal transit peptide sequence (Muta et al.,

1997). We confirmed this mitochondrial localization in U-2 OS cells

expressing Tom22-mCherry transiently transfected with a YBAP1-GFP

construct (Figure 4c-d). We also showed that YBAP1 is localized within

mitochondria by performing a proteinase K protection assay on purified

mitochondria. Mitochondria were isolated from non-transfected cells and

exposed to proteinase K in the presence or absence of Triton X-100 and

the degradation of YBAP1 was evaluated by immunoblot. YBAP1 was

resistant to proteinase K digestion as was the mitochondrial inner

membrane marker Tim23. Both were degraded by proteinase treatment in

the presence of Triton X-100 (Figure 4e), consistent with the localization of

YBAP1 within mitochondria.

To test whether YBAP1 was bound to miR223 in mitochondria, we used

YBAP1 immunoprecipitation with mitochondria purified by fractionation on a

Percoll density gradient (Figure 4f). RT qPCR data showed that

mitochondrial miR223 was immunoprecipitated by YBAP1 antibody but not

by a control antibody (Figure 4g). To determine whether the YBAP1 and

miR223 interaction was direct, we used the EMSA assay and found that

purified YBAP1 bound miR223, but not miR190. The YBAP1 interaction

with miR223 was not dependent on the RNA sequence motif responsible

for YBX1 binding (Figure 4 supplement 2a-b). Taken together, these data

suggest that YBAP1 binds miR223 in mitochondria and *in vitro*.

YBAP1 may control the transit of miR223 from mitochondria to

exosomes

To investigate the function of YBAP1 in the transit of miR223 into

exosomes, we generated a 293T YBAP1 KO cell line and compared the

level of miR223 enrichment in exosomes and mitochondria isolated from

WT and mutant cells (Figure 5a, b). Although knockout of YBAP1 did not

change exosome secretion (Figure 5 supplement 1a), RT-qPCR analysis

showed that miR223 decreased 2-fold in mitochondria but increased 8-fold

in exosomes purified from mutant and WT cells, respectively (Figure 5c).

This apparent inverse relationship is consistent with a role for YBAP1

protein in the retention of miR223 in mitochondria.

YBX1 puncta shuttled from mitochondria to endosomes

In previous work we reported the localization of YBX1 to P-bodies and

suggested this may represent an intermediate stage in the concentrative

sorting of miRNAs for secretion in exosomes (Liu *et al.*, 2021). In other

earlier work, P-bodies were seen in association with mitochondria (Huang

et al., 2011). To explore this possibility, we visualized endogenous YBX1

and YBAP1 by IF and observed YBX1 puncta colocalized with mitochondria

(Figure 6a, b). In order to detect the proximity of endosomes to this point of

contact between YBX1 puncta and mitochondria, we used U-2 OS cells

transfected with Rab5(Q79L)-mCherry, which we employed previously to

enlarge and detect the internalization of YBX1 into endosomes (Liu *et al.*,

2021). We then used three color visualization of the U-2 OS cells also

transfected with YFP-YBX1 and mito-BFP. Time-lapse imaging showed

YBX1 puncta in close proximity to mitochondria or endosomes, followed

quickly by transfer between them (Figure 6c, d). Taken together, these data

suggest a mechanism whereby miR223 stored in mitochondria, possibly

sequestered by YBAP1, may be captured in a tighter interaction with YBX1

in P-bodies and delivered to endosomes for sorting and secretion in

exosomes.

Discussion

Selected miRNAs are sorted, some with very high fidelity, into invaginations

in the endosome that give rise to exosomes secreted from cultured human

cells and likely from many if not all cells in metazoan organisms. The

means by which these miRNAs are sorted and the possible extracellular

functions they serve is a subject of interest in normal and disease

physiology. Here we report the role of the RNA-binding protein YBX1 and

a sorting or structural signal on one target RNA, miR223, and the indirect

path miR223 may take from storage in mitochondria into exosomes.

We have identified a sequence motif on miR223, UCAGU, responsible for

high affinity interaction with YBX and for sorting into vesicles formed in a

cell-free reaction as well as for secretion in exosomes by HEK293 cells.

Previously we performed this in vitro packaging assay in the presence of an inhibitor (GW4869) of neutral sphingomyelinase (NS2). This inhibitor has been shown to reduce the secretion of exosomes and exosome-associated miRNAs in other studies (Li et al., 2013; Trajkovic et al., 2008; Yuyama et al., 2012). In our cell-free assay, GW4869 inhibited the protection of CD63-luciferase and miR-223 at concentrations known to inhibit the activity of NS2 in partially purified enzyme fractions (Shurtleff *et al.*, 2016). We concluded that our cell-free reaction provides a model that mimics aspects of exosome biogenesis.

The YBX1 protein has three distinct domains, one of which, the cold-shock domain (CSD) appears to be the principal site for RNA binding, including at least one critical residue, F85, required for binding miR223 as well as other RNAs (Lyons *et al.*, 2016). The C-terminal domain (CTD) includes an intrinsically disordered domain (IDR) that promotes the formation of a liquid-liquid phase separation likely responsible for the organization of YBX1 in P-bodies (Liu *et al.*, 2021). This domain does not itself interact with RNA, but it appears to facilitate the folding or stabilization of the CSD to promote high affinity binding to miR223.

In other work using a similar approach, we identified two separate sorting signals, a 5'UGGA and a 3'UUU, on miR122 to which the RNA-binding protein La binds *en route* to secretion in exosomes by the breast cancer cell line MDA-MB-231(Temoche-Diaz *et al.*, 2019). Other distinct sorting signals and their cognate RNA-binding proteins have been documented in different cell lines. miRNAs with a GGAG sorting motif recognized by a sumolyated form of hnRNPA2B1 was shown to be enriched in exosomes (Villarroya-Beltri *et al.*, 2013). Another sequence, AAUGC, was found to be

enriched in exosomal miRNA and dependent on the RNA-binding protein

FMR1 for miRNA secretion (Wozniak et al., 2020). Diverse cell lines and

likely tissues appear to invoke distinct sorting signals decoded by different

RNA-binding proteins. Many of the proteins may engage in biomolecular

condensates such as P-bodies as a mechanism to sort RNAs for secretion

(Liu *et al.*, 2021).

miR223 appears to be an example of a number of small nuclear-encoded

RNAs localized to mitochondria (Jeandard et al., 2019). In some cases

these RNAs, such as tRNAs, serve an essential function such as in

mitochondrial protein synthesis, however, for miRNAs with no obvious

mitochondrial genome target, the function remains unclear (Jeandard *et al.*,

2019). Nonetheless, others have documented the localization of these

miRNAs enclosed within the mitochondrion and in the case of miR223, it

appears to be tightly associated with the inner membrane. The exact

organization and function of miR223 in this location remains to be

investigated but in the context of exosomal secretion, the mitochondrial

localization appears to serve as a reservoir.

In relation to the mitochondrial localization of miR223, we found a

mitochondrial RNA-binding protein, YBAP1, that copurified with a tagged

form of YBX1 expressed in HEK293 cells. YBAP1 has previously been

reported to interact with YBX1 and independently found associated with

mitochondria where its localization is dependent on an N-terminal transit

peptide sequence (Muta *et al.*, 1997). The association of mitochondrial

YBAP1 and cytoplasmic YBX1 was reproduced by coexpression of

recombinant forms of the two proteins in baculovirus-infected SF9 cells

(Figure 4 supplement 1b). YBAP1 binds miR223 selectively but with an

affinity significantly below that of YBX1 (Figure 4h-j). Although YBX1 does not localize to the mitochondrion, the stable interaction of the complex may suggest a transient relationship, perhaps during the biogenesis of YBAP1 as it transits from the cytoplasm into the mitochondrion.

A functional relationship between YBAP1 and YBX1 is suggested by the reduction in miR223 in mitochondria and increase in secretion of miR223 in exosomes secreted from YBAP1 KO cells (Fig. 5). In contrast, removal of mitochondria by treatment of cells with CCCP resulted in an increase in cytoplasmic miR223 at the expense of secretion in exosomes (Fig. 3). Although YBAP1 may facilitate the retention of miR223 within mitochondria, mitochondrial RNA import and export may serve an independent role in the selective capture of miRNAs by YBX1 in cytoplasmic P-body condensates. YBX1 puncta appear to shuttle between mitochondria and endosomes at which point miR223 bound to YBX1 may be further sorted into invaginations budding into the interior of endosomes.

The highly selective nature of miRNA sorting and secretion in exosomes suggests an important role in the trafficking of miRNAs between cells. Numerous studies have suggested a role for secreted miRNAs in recipient cells (Cha et al., 2015; Mittelbrunn et al., 2011; Pegtel et al., 2010; Valadi et al., 2007). Nonetheless, as miRNAs ordinarily act stoichiometrically on target mRNAs, the extremely low abundance and copy number of miRNAs/vesicle is hard to reconcile with such a functional role of secreted miRNA (Chevillet et al., 2014; Shurtleff et al., 2017) . Our observation that the bulk of cellular miR223 is held within mitochondria suggests an alternative role in some structural or regulatory process, perhaps essential

380   for mitochondrial homeostasis, controlled by the selective extraction of

381   unwanted miRNA into RNA granules and further by secretion in exosomes.

Materials and methods

Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Cell line (Spodoptera frugiperda)	Sf9	Other		Cell culture facility at UC Berkeley
Cell line (Homo sapiens)	HEK 293T cells	Other		Cell culture facility at UC Berkeley
Cell line (Homo sapiens)	HEK 293T-YBX1 KO cells	Other		Obtained by CRISPR-Cas9 in Schekman Lab
Cell line (Homo sapiens)	HEK 293T-YBAP1 KO	This study		Obtained by CRISPR-Cas9 in Schekman Lab
Cell line (Homo sapiens)	HEK 293T-3xHA-EGFP-OMP25	This study		Obtained by overexpression of pLJM1-3XHA-EGFP-OMP25 in Schekman lab
Cell line (Homo sapiens)	U-2OS cells	Other		Cell culture facility at UC Berkeley
Cell line (Homo sapiens)	U-2OS Parkin-GFP cells	This study		Obtained by overexpression of Parkin-GFP in Schekman lab
Recombinant DNA reagent	pFastBac His6 MBP N10 TEV LIC	Addgene	RRID: Addgene_30116	N/A

Recombinant DNA reagent	cloning vector (4C)			
Recombinant DNA reagent	Tom22-mCherry (plasmid)	This study		Gift of Dr Li Yu lab
Recombinant DNA reagent	His-MBP-YBX1 (plasmid)	This study		To express YBX1 in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(1-51) (plasmid)	This study		To express YBX1(1-51) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(52-129) (plasmid)	This study		To express YBX1(52-129) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(130-324) (plasmid)	This study		To express YBX1(1-51) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(1-129) (plasmid)	This study		To express YBX1(1-129) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(F85A) (plasmid)	This study		To express YBX1(F85A) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBAP1 (plasmid)	This study		To express YBAP1 in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	Mito-BFP	This study		Gift of Dr. Samantha Lewis lab
Recombinant DNA reagent	mCherry-Rab5(Q79L)	Addgene	RRID: Addgene_35138	

	(plasmid)			
Recombinant DNA reagent	pLJM1-3XHA-EGFP-OMP25	This study		To express 3xHA-EGFP-OMP25 in HEK293T cells. Plasmid maintained in Schekman lab
Antibody	Anti-YBX1 (Rabbit polyclonal)	Abcam	RRID: AB_1950384	WB 1:1000
Antibody	Anti-YBAP1 (Mouse monoclonal)	Santa Cruz	RRID: AB_10611471	WB 1:1000
Antibody	Anti-YBAP1(Rabbit polyclonal)	Thermo Fisher Scientific	RRID: AB_2638956	WB 1:1000
Antibody	Anti-Tim23 (Mouse monoclonal)	BD Biosciences	RRID: AB_398754	WB 1:1000
Antibody	Anti-Tom20 (Mouse monoclonal)	Abcam	RRID: AB_945896	WB 1:1000
Antibody	Anti-Calnexin (Rabbit polyclonal)	Abcam	RRID: AB_2069006	WB 1:2000
Antibody	Anti-HA (Rabbit monoclonal)	Cell Signaling	RRID: AB_1549585	WB 1:1000
Antibody	Anti-COX IV (Rabbit Monoclonal)	Cell signaling	RRID: AB_2085424	WB 1:1000
Antibody	Anti-Citrate Synthase (Rabbit monoclonal)	Cell signaling	RRID: AB_2665545	WB 1:1000
Antibody	Anti-Rab5 (Rabbit monoclonal)	Cell signaling	RRID: AB_2300649	WB 1:1000
Antibody	Anti-LAMP1 (Rabbit monoclonal)	Cell signaling	RRID: AB_2687579	WB 1:1000
Antibody	Anti-GRP78 (Rabbit polyclonal)	Abcam	RRID: AB_2119834	WB 1:3000
Antibody	Anti-GADPH	Cell signaling	RRID: AB_561053	WB 1:5000

	(Rabbit monoclonal)			
Antibody	Anti-alpha Tubulin (Mouse monoclonal)	Abcam	RRID: AB_2241126	WB 1:5000
Antibody	Anti-beta Actin (Mouse monoclonal)	Abcam	RRID: AB_449644	WB 1:5000
Software, algorithm	Image Studio Lite	LICOR		https://www.licor.com/bio/image-studio-lite/
Software, algorithm	FIJI	NIH	RRID: SCR_002285	https://fiji.sc/
Software, algorithm	Prism 9	GraphPad	RRID: SCR_002798	https://www.graphpad.com

Cell lines and cell culture

All immortalized cell lines were obtained from the UC-Berkeley Cell Culture

Facility and were confirmed by short tandem repeat (STR) profiling and

tested negative for mycoplasma contamination. HEK 293T cells were

cultured in DMEM with 10% FBS(VWR), NEAA (Gibco, Cat No: 11140050)

and 1mM Sodium Pyruvate (Gibco, Cat No: 11360070). For exosome

production, we seeded cells at 10~20% confluency in 150 mm tissue

culture dishes (Fisher Scientific, Cat No: 12-565-100) containing 30ml of

exosome-free medium. Exosomes were collected from 80% confluent cells

(~48h).

Exosome purification

397 Conditioned medium was harvested from 80-90% confluent HEK 293T

398 cultured cells. All procedures were performed at 4 ℃. Cells and large debris

were removed by centrifugation in a Sorvall R6+ centrifuge at 1,000xg for 15 min followed by 10,000xg for 15 min using a FIBERlite F14-6x500y rotor. The supernatant fraction was then centrifuged onto a 60% sucrose cushion in a buffer with 10mM HEPES (pH 7.4) and 0.85% w/v NaCl at ~100,000 x g (28,000 RPM) for 1.5h in a SW32Ti rotor. The interface over the sucrose cushion was collected and pooled for an additional centrifugation onto a 2ml 60% sucrose cushion at ~120,000 x g (31,500 RPM) for 15h using an SW41Ti rotor. The first collected interface was measured by refractometry and adjusted a sucrose concentration not exceeding 21%. For bulk purification, the EVs collected from the interface over the sucrose cushion after the first SW41Ti centrifugation were mixed with 60% sucrose to a final volume of 10ml (the concentration of sucrose ~50%). One ml of 40% and 1ml of 10% sucrose were sequentially overlaid and the samples were centrifuged at ~150,000 x g (36,500 rpm) for 15h in an SW41Ti rotor. The exosomes were located at the 10%/40% interface and collected for RNA extraction or immunoblot.

Density gradient isolation of mitochondria and mitoplasts

Mitochondria were isolated according to a well-established published protocol (Wang *et al.*, 2020). HEK293T Cells were harvested at 80% confluency and were homogenized in 6 vol of HB buffer (225 mM mannitol, 25 mM sucrose, 0.5% BSA, 0.5 mM EGTA, 30 mM Tris–HCl, pH 7.4, and protease inhibitors) in a prechilled Dounce homogenizer (Kontes). The lysate was centrifuged and the postnuclear supernatant was collected. Crude mitochondria were centrifuged at 6,300 x g for 8 min, washed once with MRB buffer (250 mM mannitol, 0.5 mM EGTA, and 5 mM HEPES, pH 7.4), resuspended in 1ml MRB buffer, laid over a 30% Percoll solution (9ml)

and centrifuged at 95,000g for 45min. The buoyant, purified fraction of mitochondria was collected for further analysis. For mitoplast purification, crude mitochondria were resuspended into 10 vol MRB buffer with 0.2 mg/ml digitonin and incubated on ice for 15 min. Digitonin-treated crude mitochondria were laid over a 30% Percoll solution (9ml) and centrifuged at 95,000g for 45 min. A buoyant, purified fraction of mitoplasts was collected for further analysis.

YBAP1 immunoprecipitation from mitochondria

After the Percoll gradient purification, the enriched mitochondria were diluted 2x into MRB buffer and centrifuged at 12,000g for 10 min. The mitochondrial pellet was lysed in 0.5ml RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 1% DDM, 1mM PMSF) containing protease inhibitors (1mM 4-aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine chloromethyl ketone and 1 µg/ml pepstatin) and RNase inhibitors, followed by centrifugation at 12,000g for 10 min. Supernatant fractions were incubated with 10ul washed protein A Dynabeads (ThermoFisher Scientific, Catalog number: 10001D) and 0.5ug mouse monoclonal IgG antibody and rotated at 4 ℃ for 1h. A magnetic rack was used to remove protein A beads and the resulting supernatant fractions were incubated with 40ul washed protein A Dynabeads and 4ug YBAP1 antibody or mouse IgG antibody and rotated at 4 ℃ overnight. The beads were collected using a magnetic rack, washed 3x with 1ml of RIPA buffer, and collected for immunoblot and RNA extraction.

Mitochondria immunoprecipitation

Mito-IP was performed as previously described with slight modifications (Chen et al., 2016). The mito-IP cell-line was grown to ~90% confluency in 15cm dishes. All the subsequent steps of mito-IP were performed using ice-cold buffers either in a cold-room or on ice. Cells ($2x10^7$) were washed twice with 10ml of PBS and then harvested in 10ml of mito-IP buffer (10mM KH2PO4, 137mM KCl) containing protease inhibitors (1mM 4-aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine chloromethyl ketone and 1 µg/ml pepstatin) and TCEP 0.5mM. The final mito IP buffer also contained 6ml of OptiPrep^{TM} (Sigma$^®$) per 100ml. Cells were collected at 700xg for 5 min and resuspended in 1ml of mito-IP buffer per 15cm plate and then lysed using 5-10 passes through a 22G needle. A post-nuclear supernatant (PNS) fraction was obtained after centrifuging the lysate at 1500xg for 10 min to remove unbroken cells and nuclei. Whenever necessary, a fraction of PNS was saved for immunoblot analysis. The resulting PNS was incubated with 100 µl of anti-HA magnetic beads (Sigma®) pre-equilibrated in the mito-IP buffer in 1.5ml microcentrifuge tubes and then gently rotated on a mixer for 15min. The beads were collected using a magnetic rack and washed 3x for 5min with 1ml of mito-IP buffer.

For mitoplast purification by osmotic shock, the supernatant was discarded after the final wash of the mito-IP sample, and the beads were gently resuspended in 200 µl of hypotonic osmotic shock buffer (OSB) containing 20 mM HEPES at pH 7.4. The resuspended sample was incubated on ice

for 30 min and then the beads were centrifuged at 15,000 g for 15 min to sediment mitochondria/mitoplasts. Beads were then resuspended in 100 µl of KPBS and proteinase K was added to achieve a final concentration of 10 µg/ml and samples were incubated on a rotating mixer at 4^0 C for 15 min. Subsequently, PMSF was added to a final concentration of 1 mM, along with a protease inhibitor cocktail, and the sample was incubated on ice for 5 min. Next, 2.5 units of RNase ONE (Promega) was added to the sample, which was further incubated on a rotating mixer at room temperature for 15 min. For protein analysis, the sample was eluted directly in the SDS loading buffer. Alternatively, Trizol was added to the sample to stop the reaction for RNA purification.

To assess their quality, we assayed the immunoprecipitated mitochondria for the following protein markers by immunoblotting using the rabbit primary antibodies- anti-HA (1:1000), anti-COX IV (1:1000), anti-TOM20 (1:1000), anti-Citrate Synthase (1:1000), anti-RAB5 (1:1000), anti-LAMP1 (1:2000), anti-GAPDH (1:5000), and anti-GRP78 (Abcam®) (1:3000). All of the above antibodies were sourced from Cell Signaling Technology®, unless stated otherwise. As a negative control, non-transduced HEK293T cells were used in these experiments to assess the non-specific capture of the marker proteins.

Mitochondrial Fractionation

One mito-IP was performed per sample as described above. To ensure an even distribution of mitochondria across the samples, we pooled washed beads from all the IPs and equally distributed aliquots for subsequent treatments. Mitochondria were lysed in a 50µl final volume using either 1% vol/vol Triton X-100 (final concentration) or by three sequential rounds of freeze/thaw using liquid-nitrogen, as indicated. Urea was added to a final

concentration of 3M. After a 10 min incubation on ice, samples were
centrifuged at 15000xg for 15 min and supernatant and pellet fractions
were collected as indicated. The total fractionated mitochondria were
analyzed by immunoblotting for various mitochondrial markers. To analyze
the specific RNA content of total or fractionated mitochondria, we extracted
RNA using Trizol^{TM} (Invitrogen®) as per manufacturer's recommendations
followed by q-PCR.

In vitro packaging of miR223 and miR223mut

Preparation of membranes and cytosol

The membrane and cytosol fractions were prepared from HEK293T cells as
previously described with slight modifications (Shurtleff *et al.*, 2016;
Temoche-Diaz *et al.*, 2020). All steps were carried out in either the cold-
room or on ice using ice-cold buffers and pre-chilled equipment. Briefly,
HEK293T cells (80% confluency) were washed twice with PBS and then
harvested in the homogenization buffer (HB) (250 mM sorbitol, 20mM
HEPES-KOH pH 7.4) containing protease inhibitor cocktail (1mM 4-
aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1
µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM
phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine
chloromethyl ketone and 1 µg/ml pepstatin). The cell pellet was obtained by
centrifuging the cells at 500xg for 5 min. After discarding the supernatant,
cells were weighed and resuspended in two volumes of HB followed by
lysis with 5-10 passages through a 22G needle. The lysate was centrifuged
at 1500xg for 10 min to remove unbroken cells and nuclei to obtain a PNS
which was then centrifuged at 20,000xg for 30 min to obtain a membrane
fraction. The supernatant from above was centrifuged at 150,000xg for 30
min using a TLA-55 rotor (Beckman Coulter $^®$) and the resulting
supernatant was used as the cytosol fraction (~6mg protein/ml).
Membranes from the first 20,000xg sedimentation were resuspended in 1
ml of HB and centrifuged again at 20,000xg for 30 min. The pellet fraction
was resuspended in one volume of HB and rested on an ice block for a
minimum of 10 min until the insoluble components and debris settled at the
bottom of the tube. The finely resuspended material in the resulting
supernatant fraction was then transferred to a new microcentrifuge tube (to
avoid the settled debris) and was used as the membrane fraction.

Preparation of radiolabeled miR223 and miR223mut substrates

HPLC purified miR223 and miR223mut oligos were obtained from IDT®. A
stock solution of these oligos (1µl of a 10µM) was 5'-end-labeled using
T4PNK (NEB®) and 5µl of ATP, [γ-32P]- 6000Ci/mmol 10mCi/ml EasyTide
(PerkinElmer® BLU502Z250UC) as per manufacturer's recommendations
in a 50µl reaction volume. T4PNK was heat-inactivated at 70°C for 15 min.
Unincorporated radionucleotides were removed by passing through
PerformaTM spin columns (EdgeBio®). The flow-through (radiolabeled
substrate) was collected and stored at -20°C until further use.

In vitro miR223 packaging reaction

Wherever indicated, 10µl of cytosol (~5 mg/ml), 17µl of membranes, 2µl of
radiolabeled substrate, 9µl of 5x incorporation buffer (400 mM KCl, 100 mM
$CaCl_2$, 60 mM HEPES-NaOH, pH 7.4, 6 mM, MgOAc), 4.5µl of 10x ATP
regeneration system (400 mM creatine phosphate, 2 mg/ml creatine
phosphokinase, 10 mM ATP, 20 mM HEPES pH 7.2, 250 mM sorbitol, 150
mM KOAc, 5 mM MgOAc), 1µl of ATP (100mM, Promega®), 0.5µl of GTP
(100mM, Promega®), 1µl of Ribolock™ (40U/µl, Invitrogen®) were mixed to
setup a 45µl *in vitro* packaging reaction. In samples without the cytosol or
membranes, the final reaction volumes were adjusted to 45µl using HB.
The reactions were incubated at either 30°C or on ice, as indicated, for 15
min. Following the incubation, the indicated samples were subjected to
RNAse ONE™ (Promega®) using 10U of the enzyme in the presence of
urea (300mM final concentration) in a total reaction volume of 60µl.
Wherever indicated, TritonX-100 was added to a final concentration of 1%.
The RNAse treatments were carried out for 20 min at 30°C followed by
RNA extraction using DirectZol™ (Zymo Research®) kits as per
manufacturer's protocol. RNA was precipitated overnight at -20°C by the
addition of 3 vol of ethanol, 1/10th volume of 3M sodium acetate (pH5.2)
and 30µg Glycoblue™ reagent (Invitrogen®). Precipitated RNA was
sedimented at 16,000xg for 30 min followed by washing with ice-cold 70%
ethanol. The RNA pellet was resuspended in 2X RNA loading dye (NEB®)
and heated for 5 min at 70°C. RNA was separated using a 15% denaturing
polyacrylamide gel, followed by gel drying using a vacuum gel dryer (Model
583, Biorad®). Radioactive bands were visualized by phosphorimaging

using a Kodak® storage phosphor screen and the Pharos FX^TM Plus
Molecular Imager (Biorad®).

Immunoblots

Cell lysates and other samples were prepared by adding 2% SDS and

heated at 95 ℃ for 10min. Protein was quantified using a BCA Protein

Assay Kit (Thermo Fisher Scientific) and appropriate amounts were mixed

with 5x SDS loading buffer. Samples were heated at 95℃ for 10min and

separated on 4–20% acrylamide Tris-glycine gradient gels (Life

Technologies). Proteins were transferred to PVDF membranes (EMD

Millipore, Darmstadt, Germany) and the membrane was blocked with 5%

fat-free milk powder in TBST and incubated for 1 h at room temperature or

overnight at 4°C with primary antibodies. Blots were then washed in 3

washes of TBST for 10 min each. Membranes were incubated with anti-

rabbit or anti-mouse secondary antibodies (GE Healthcare Life Sciences,

Pittsburgh, PA) for 1h at room temperature and rinsed in 3 washes of TBST

for 10 min each. Blots were developed with ECL-2 reagent (Thermo Fisher

Scientific). Primary antibodies used in this study were as follows: anti-

Tim23 (BD, 611222), Calnexin (Abcam, ab22595), Actin (Abcam, ab8224),

Tubulin (Abcam, ab7291), YBAP1 (Santa Cruz Biotechnology, sc-271200).

Immunofluorescence

Cells were cultured on 12mm round coverslips (corning) and were fixed

with 4% EM-grade paraformaldehyde (Electron Microscopy Science,

Hatfield, PA) in PBS pH7.4 for 10 min at room temperature. Cells were then

washed 3x with PBS for 10min each, treated with permeabilizing buffer (10%

FBS in PBS) containing 0.1% saponin for 20min and treated in blocking

buffer for 30min. Subsequently, cells were incubated with primary antibodies in permeabilizing buffer for 1h at room temperature, washed 3x with PBS for 10 min each and incubated with secondary antibodies in permeabilizing buffer for 1h at room temperature and finally washed 3x with PBS for 10 min each. Cells were mounted on slides with Prolong Gold with DAPI (Thermo Fisher Scientific, P36931). Primary antibodies used in the immunofluorescence studies were as follows: anti-YBX1 (Abcam, ab12148), YBAP1 (Santa Cruz Biotechnology, sc-271200). Images were acquired with Zeiss LSM900 confocal microscope and analyzed with the Fiji software (http://fiji.sc/Fiji).

Quantitative real-time PCR

Cellular and EV RNAs were extracted using a mirVana miRNA isolation kit (Thermo Fisher Scientific, AM1560) or Direct-zol RNA Miniprep kits (Zymo Research). Taqman miRNA assays for miRNA detection were purchased from Life Technologies. Assay numbers were: hsa-miR-223-3p, 002295; hsa-mir-190–5 p, 000489; U6 snRNA, 001973. Total RNAs were quantified using RNA bioanalyzer (Agilent). Taqman qPCR master mix with no Amperase UNG was obtained from Life Technologies for reverse transcription. For mRNA, RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, K1621) was used for reverse transcription. COX1 qPCR primers: Forward-5'-TCTCAGGCTACACCCTAGACCA-3', Reverse-5'-ATCGGGGTAGTCCGAGTAACGT-3'. GAPDH qPCR primers: Forward-5'-CTGACTTCAACAGCGACACC-3', Reverse-5'-TAGCCAAATTCGTTGTCATACC-3'. Quantitative real-time PCR was performed using an QuantStudio™ 5 Real-Time PCR System (Applied Biosystems™)

Protein Purification

Twin Strep tag hybrid YBX1 was expressed and the protein was isolated 48h after PEI-mediated transfection of 293T cells. Cells were resuspended in PBS and collected by centrifugation for 5 min at 600g. Pellet fractions were resuspended in 35 ml lysis buffer (50mM Tris-HCl (pH 8),150mM NaCl,1mM EDTA, 2mM DTT, 1mM PMSF and 1 x protease inhibitor cocktail). After sonication of the cell suspension the crude lysate was centrifuged for 60 min at 20,000 rpm at 4 °C. The resulting supernatant fraction was incubated with 2 ml Strep-Tactin® Sepharose® resin (IBA, 2-1201-010) for 1 h. Strep-Tactin® Sepharose® resin samples were transferred to columns (18ml) and protein-bound beads were washed with 60ml wash buffer (50mM Tris-HCl (pH 8), 500mM NaCl, 1mM EDTA, 2mM DTT) until no protein was eluted as monitored by the Bio-Rad protein assay (Bio-Rad, Catalog #5000006). Proteins were eluted with 10 ml elution buffer (50mM Tris-HCl (PH=8),150mM NaCl, 10mM desthiobiotin, 1mM EDTA, 2mM DTT) and concentrated using an Amicon Ultra Centrifugal Filter Unit (50 kDa, 4 ml) (Fisher Scientific, EMD Millipore). Proteins were further purified by gel filtration chromatography (Superdex-200, GE Healthcare) with columns equilibrated in storage buffer (50 mM Tris-HCl 7.4, 500 mM KCl, 5 % glycerol, 1 mM DTT). Peak fractions corresponding to the appropriate fusion protein were pooled, concentrated, and distributed in 10 µl aliquots in PCR tubes, flash-frozen in liquid nitrogen and stored at -80 °C. Protein concentration was determined by known concentrations of BSA assessed by Coomassie Blue staining.

Tagged (6xHis) and maltose-binding protein hybrid genes were expressed in baculovirus-infected SF9 insect cells (Lemaitre et al., 2019). Insect cell

cultures (1 l, 1x10^6 cells/ml) were harvested 48 h after viral infection and

collected by centrifugation for 20 min at 2000 rpm. The pellet fractions were

resuspended in 35 ml lysis buffer (50 mM Tris-HCl 7.4, 0.5 M KCl, 5 %

glycerol, 10mM imidazole, 0.5 µl/ml Benzonase nuclease (Sigma, 70746–3),

1 mM DTT, 1 mM PMSF and 1 x protease inhibitor cocktail). Cells were

lysed by sonication and the crude lysate was centrifuged for 60 min at 20,

000 rpm at 4 °C. After centrifugation, the supernatant fraction was

incubated with 2 ml Ni-NTA His-Pur resin (Thermo Fisher, PI88222) for 1 h.

Ni-NTA resin samples were transferred to columns (18ml) and protein-

bound beads were washed with 60ml lysis buffer until no protein was eluted

as monitored by the Bio-Rad protein assay (Bio-Rad, Catalog #5000006).

Proteins were eluted with 10 ml elution buffer (50 mM Tris-HCl 7.4, 0.5 M

KCl, 5 % glycerol, 500mM imidazole). The eluted sample was incubated

with 2 ml amylose resin (New England Biolabs, E8021L) for 1 h at 4°C.

Amylose resin samples were transferred to columns and protein-bound

beads were washed with 60ml lysis buffer until no protein was eluted as

monitored by the Bio-Rad protein assay. Proteins were eluted with 10 ml

elution buffer (50 mM Tris-HCl 7.4, 500 mM KCl, 5 % glycerol, 50 mM

maltose) and were concentrated using an Amicon Ultra Centrifugal Filter

Unit (50 kDa, 4 ml) (Fisher Scientific, EMD Millipore). Proteins were further

purified by gel filtration chromatography (Superdex-200, GE Healthcare)

with columns equilibrated in storage buffer (50 mM Tris-HCl 7.4, 500 mM

KCl, 5 % glycerol, 1 mM DTT). Peak fractions corresponding to the

appropriate fusion protein were pooled, concentrated, and distributed in 10

µl aliquots in PCR tubes, flash-frozen in liquid nitrogen and stored at –

80 °C. Protein concentration was determined by known concentrations of

BSA based on Coomassie blue staining.

CRISPR/Cas9 genome editing

A pX330-based plasmid expressing Venus fluorescent protein (Shurtleff *et al.*, 2016) was used to clone the gRNAs targeting YBAP1. A CRISPR guide RNA targeting the first exon of the YBAP1 open reading frame was designed following the CRISPR design website (http://crispor.tefor.net/crispor.py): CGCTGCGTGCCCCGTGTGCT. Oligonucleotides encoding gRNAs were annealed and cloned into pX330-Venus as described (Cong et al., 2013). HEK293T cells were transfected by Lipofectamine 2000 for 48h at low passage number, trypsinized and sorted for single, Venus positive cells in 96 well plates by a BD Influx cell sorter. YBAP1 knockout candidates were confirmed by immunoblot. HEK 293T YBX1 knockout cells were generously provided by Dr. Xiaoman Liu (Liu *et al.*, 2021).

Electrophoretic mobility shift assay

Fluorescently labeled RNAs (5'-IRD800CWN) for detecting free and protein-bound RNA were ordered from Integrated DNA Technologies (IDT, Coralville, IA). EMSA was performed as described with some modification (Rio, 2014). Briefly, 1 nM of IRD800CWN-labeled RNA was incubated with increasing amounts of purified proteins, ranging from 500 pM - 1 μM. Buffer E was used in this incubation (25 mM Tris pH8.0, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EGTA, 0.05% Nonidet P-40, 1 mM DTT, 5% glycerol, 50 ug/ml heparin). Reactions were incubated at 30 ℃ for 30min then chilled on ice for 10 min. Samples were mixed with 6x loading buffer (60 mM KCl, 10 mM Tris pH 7,6, 50% glycerol, 0.03% (w/v) xylene cyanol). Mixtures (5ul) were loaded onto a 6% native polyacrylamide gel and electrophoresed

at 200V for 45mins in a cold room. The fluorescence signal was detected using an Odyssey CLx Imaging System (LI-COR Biosciences, Lincoln, NE). The software of the Odyssey CLx Imaging System was used to quantify fluorescence. To calculate Kds, we fitted used Hill equations with quantified data points.

CD63-Nluc exosome secretion assay

The CD63-Nluc exosome secretion assay was carried out as described (Williams et al., 2023). Briefly, cells stably expressing CD63-Nluc were cultured in 24-well plates until reaching approximately 80% confluence. All subsequent procedures were performed at 4°C. Conditioned medium (200 µl) was collected from the appropriate wells and transferred to microcentrifuge tubes. The tubes were subjected to centrifugation at 1000 × g for 15 min to remove intact cells, followed by an additional centrifugation at 10,000 × g for 15 min to eliminate cellular debris. Supernatant fractions (50 µl) were used for measuring CD63-Nluc exosome luminescence. Cells were kept on ice and washed once with cold PBS, and then lysed in 200 µl of PBS containing 1% TX-100 and protease inhibitor cocktail.

For the measurement of CD63-Nluc exosome secretion, a master mix was prepared by diluting the Extracellular NanoLuc Inhibitor at a 1:1000 ratio and the NanoBRET Nano-Glo Substrate at a 1:333 ratio in PBS (Promega, Madison, WI, USA). Aliquots of the Nluc substrate/inhibitor master mix (100 µl) were added to 50 µl of the supernatant fraction obtained from the medium-speed centrifugation. The mixture was briefly vortexed, and luminescence was measured using a Promega GlowMax 20/20

Luminometer (Promega, Madison, WI, USA). Following luminescence measurements, 1.5 μl of 10% TX-100 was added to each reaction tube to achieve a final concentration of 0.1% TX-100. Samples were vortexed briefly, and luminescence was measured again. For intracellular normalization, the luminescence of 50 μl of cell lysate was measured using the Nano-Glo Luciferase Assay kit (Promega, Madison, WI, USA) following the manufacturer's instructions. The exosome production index (EPI) for each sample was calculated using the formula: EPI = ([medium] - [medium + 0.1% TX-100])/cell lysate.

Data availability

All data generated or analyzed in this study are included in the manuscript and supporting files. Source data files have been provided for Figure 1b, Figure 1c, Figure 1f, Figure 1g, Figure 1-figure supplement 2a-c, Figure 2b, Figure 2g, Figure 2-figure supplement 1a-f, Figure 3a, Figure 3c, Figure 3e, Figure 3h, Figure 3 supplement 1b-c, Figure 4a, Figure 4b, Figure 4e, Figure 4f, Figure 4h, Figure 4i, Figure 4-figure supplement 1a-b, Figure 4-figure supplement 2a, Figure 5b.

Funding

Howard Hughes Medical Institute (Investigator)

Randy Schekman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Dr. Samantha Lewis for advice about localization to mitochondria and for sharing a plasmid; thanks Matthew J Shurtleff, David Melville, Shenjie Wu, Jordan Ngo, Congyan Zhang, Justin Williams, Morayma M Temoche-Diaz for suggestions and reading and editing the manuscript. We also thank staff at the UC Berkeley shared facilities, the Cell Culture Facility, the Flow Cytometry Facility and QB3-Berkeley (The California Institute for Quantitative Biosciences at UC Berkeley). LM and JS are supported as Research Associates of the HHMI. RS is an Investigator of the HHMI, a Senior fellow of the UC Berkeley Miller Institute of Science and Scientific Director of Aligning Science Across Parkinson's Disease.

References

Cha, D.J., Franklin, J.L., Dou, Y., Liu, Q., Higginbotham, J.N., Demory Beckler, M., Weaver, A.M., Vickers, K., Prasad, N., Levy, S., et al. (2015). KRAS-dependent sorting of miRNA to exosomes. Elife *4*, e07197. 10.7554/eLife.07197.

Chen, W.W., Freinkman, E., Wang, T., Birsoy, K., and Sabatini, D.M. (2016). Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell *166*, 1324-1337 e1311. 10.1016/j.cell.2016.07.040.

Chevillet, J.R., Kang, Q., Ruf, I.K., Briggs, H.A., Vojtech, L.N., Hughes, S.M., Cheng, H.H., Arroyo, J.D., Meredith, E.K., Gallichotte, E.N., et al. (2014). Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A *111*, 14888-14893. 10.1073/pnas.1408301111.

Cocucci, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol *19*, 43-51. 10.1016/j.tcb.2008.11.003.

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X.,
Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering
using CRISPR/Cas systems. Science *339*, 819-823. 10.1126/science.1231143.
Correia-Melo, C., Ichim, G., Tait, S.W., and Passos, J.F. (2017). Depletion of
mitochondria in mammalian cells through enforced mitophagy. Nat Protoc *12*,
183-194. 10.1038/nprot.2016.159.
Harding, C., Heuser, J., and Stahl, P. (1983). Receptor-mediated endocytosis of
transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol
97, 329-339. 10.1083/jcb.97.2.329.
Huang, L., Mollet, S., Souquere, S., Le Roy, F., Ernoult-Lange, M., Pierron, G.,
Dautry, F., and Weil, D. (2011). Mitochondria associate with P-bodies and
modulate microRNA-mediated RNA interference. J Biol Chem *286*, 24219-24230.
10.1074/jbc.M111.240259.
Jeandard, D., Smirnova, A., Tarassov, I., Barrey, E., Smirnov, A., and Entelis, N.
(2019). Import of Non-Coding RNAs into Human Mitochondria: A Critical
Review and Emerging Approaches. Cells *8*. 10.3390/cells8030286.
Li, J., Liu, K., Liu, Y., Xu, Y., Zhang, F., Yang, H., Liu, J., Pan, T., Chen, J., Wu,
M., et al. (2013). Exosomes mediate the cell-to-cell transmission of IFN-alpha-
induced antiviral activity. Nat Immunol *14*, 793-803. 10.1038/ni.2647.
Liu, X.M., Ma, L., and Schekman, R. (2021). Selective sorting of microRNAs into
exosomes by phase-separated YBX1 condensates. Elife *10*. 10.7554/eLife.71982.
Lyons, S.M., Achorn, C., Kedersha, N.L., Anderson, P.J., and Ivanov, P. (2016).
YB-1 regulates tiRNA-induced Stress Granule formation but not translational
repression. Nucleic Acids Res *44*, 6949-6960. 10.1093/nar/gkw418.
Matsumoto, K., Tanaka, K.J., and Tsujimoto, M. (2005). An acidic protein,
YBAP1, mediates the release of YB-1 from mRNA and relieves the translational
repression activity of YB-1. Mol Cell Biol *25*, 1779-1792.
10.1128/MCB.25.5.1779-1792.2005.
Mittelbrunn, M., Gutierrez-Vazquez, C., Villarroya-Beltri, C., Gonzalez, S.,
Sanchez-Cabo, F., Gonzalez, M.A., Bernad, A., and Sanchez-Madrid, F. (2011).
Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-
presenting cells. Nat Commun *2*, 282. 10.1038/ncomms1285.
Mukherjee, K., Ghoshal, B., Ghosh, S., Chakrabarty, Y., Shwetha, S., Das, S., and
Bhattacharyya, S.N. (2016). Reversible HuR-microRNA binding controls
extracellular export of miR-122 and augments stress response. EMBO Rep *17*,
1184-1203. 10.15252/embr.201541930.
Muta, T., Kang, D., Kitajima, S., Fujiwara, T., and Hamasaki, N. (1997). p32
protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix
and is functionally important in maintaining oxidative phosphorylation. J Biol
Chem *272*, 24363-24370. 10.1074/jbc.272.39.24363.

Pegtel, D.M., Cosmopoulos, K., Thorley-Lawson, D.A., van Eijndhoven, M.A., Hopmans, E.S., Lindenberg, J.L., de Gruijl, T.D., Wurdinger, T., and Middeldorp, J.M. (2010). Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A *107*, 6328-6333. 10.1073/pnas.0914843107.

Rio, D.C. (2014). Electrophoretic mobility shift assays for RNA-protein complexes. Cold Spring Harb Protoc *2014*, 435-440. 10.1101/pdb.prot080721.

Santangelo, L., Giurato, G., Cicchini, C., Montaldo, C., Mancone, C., Tarallo, R., Battistelli, C., Alonzi, T., Weisz, A., and Tripodi, M. (2016). The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep *17*, 799-808. 10.1016/j.celrep.2016.09.031.

Shurtleff, M.J., Temoche-Diaz, M.M., Karfilis, K.V., Ri, S., and Schekman, R. (2016). Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. Elife *5*. 10.7554/eLife.19276.

Shurtleff, M.J., Yao, J., Qin, Y., Nottingham, R.M., Temoche-Diaz, M.M., Schekman, R., and Lambowitz, A.M. (2017). Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc Natl Acad Sci U S A *114*, E8987-E8995. 10.1073/pnas.1712108114.

Temoche-Diaz, M.M., Shurtleff, M.J., Nottingham, R.M., Yao, J., Fadadu, R.P., Lambowitz, A.M., and Schekman, R. (2019). Distinct mechanisms of microRNA sorting into cancer cell-derived extracellular vesicle subtypes. Elife *8*. 10.7554/eLife.47544.

Temoche-Diaz, M.M., Shurtleff, M.J., and Schekman, R. (2020). Buoyant Density Fractionation of Small Extracellular Vesicle Sub-populations Derived from Mammalian Cells. Bio Protoc *10*, e3706. 10.21769/BioProtoc.3706.

Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M.L., et al. (2017). MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat Commun *8*, 14448. 10.1038/ncomms14448.

Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brugger, B., and Simons, M. (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science *319*, 1244-1247. 10.1126/science.1153124.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lotvall, J.O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol *9*, 654-659. 10.1038/ncb1596.

Villarroya-Beltri, C., Gutierrez-Vazquez, C., Sanchez-Cabo, F., Perez-Hernandez, D., Vazquez, J., Martin-Cofreces, N., Martinez-Herrera, D.J., Pascual-Montano, A., Mittelbrunn, M., and Sanchez-Madrid, F. (2013). Sumoylated hnRNPA2B1

controls the sorting of miRNAs into exosomes through binding to specific motifs.
Nat Commun *4*, 2980. 10.1038/ncomms3980.
Wang, W.X., Prajapati, P., Nelson, P.T., and Springer, J.E. (2020). The
Mitochondria-Associated ER Membranes Are Novel Subcellular Locations
Enriched for Inflammatory-Responsive MicroRNAs. Mol Neurobiol *57*, 2996-
3013. 10.1007/s12035-020-01937-y.
Williams, J.K., Ngo, J.M., Lehman, I.M., and Schekman, R. (2023). Annexin A6
mediates calcium-dependent exosome secretion during plasma membrane repair.
Elife *12*. 10.7554/eLife.86556.
Wozniak, A.L., Adams, A., King, K.E., Dunn, W., Christenson, L.K., Hung, W.T.,
and Weinman, S.A. (2020). The RNA binding protein FMR1 controls selective
exosomal miRNA cargo loading during inflammation. J Cell Biol *219*.
10.1083/jcb.201912074.
Yuyama, K., Sun, H., Mitsutake, S., and Igarashi, Y. (2012). Sphingolipid-
modulated exosome secretion promotes clearance of amyloid-beta by microglia. J
Biol Chem *287*, 10977-10989. 10.1074/jbc.M111.324616.

Figure legends

Figure 1. YBX1 directly and specifically binds miR223.

(a.) RT-qPCR analysis of fold change of miR-223 and miR-190 in cells and
purified exosomes from 293T WT cells and YBX1 knockout cells. Data are
plotted from 3 independent experiments, each independent experiment with
triplicate qPCR reactions; error bars represent standard deviations. (b-c.)
EMSA assays using 1nM 5' fluorescently labeled miR223 or miR190 and
purified YBX1. Purified YBX1 was titrated from 500pM to 1μM. In gel
fluorescence was detected. Quantification of (d.) shows the calculated Kd.
(e.) Schematic diagrams of the different domains of YBX1. (f.) EMSA assay
using 1nM 5' fluorescently labeled miR223 and purified YBX1 truncations.
[YBX1(1-51) or YBX1(52-129) or YBX1(130-324).] (g.) EMSA assay using
1nM 5' fluorescently labeled miR223 and purified YBX1 truncations
[YBX1(1-129) or YBX1(52-324)] or YBX1(F85A) mutant.

Figure 1-figure supplement 1. Knockout of YBX1 did not change exosome secretion.

(a.) Exosome numbers are measured by Nanosight NS300. Normalized exosome number from 293T WT and YBX1-KO cells are shown.

Figure 1-figure supplement 2. Purified YBX1 full length protein and different truncations and mutation.

(a-c.) YBX1 full length protein or different truncations were overexpressed and purified from insect cells.

Figure 2. miR223 sequence motif UCAGU binds YBX1

(a.) RNA oligonucleotides corresponding to miR223, miR190 and versions with mutated sorting motif (miR223mut) or mutation to introduce the sorting motif (miR190sort). (b.) EMSA assays using 1nM 5' fluorescently labeled miR223 WT or miR223mut or miR190 WT or miR190sort and purified YBX1. Purified YBX1 was titrated from 500pM to 1μM. In gel fluorescence was detected. (c.) Binding affinity curves as calculated by EMSA data from (b.) (d.) Schematic shows exosome purification with buoyant density flotation in a sucrose step gradient from 293T cells overexpressing miR223 WT or mutant or miR190 WT or miR190sort. (e.) RT-qPCR analysis of relative abundance of miR223 or miR223mut detected in exosomes compared to cellular level in 293T cells overexpressing miR223 WT or miR223mut. Data are plotted from 3 independent experiments and error bars represent standard deviations. (f.) RT-qPCR analysis of relative abundance of miR190 or miR190sort detected in exosomes compared to cellular level in 293T cells overexpressing miR190 WT or miR190sort. Data are plotted from 3 independent experiments and error bars represent

standard derivations. (g.) *In vitro* packaging assay using ^{32}P 5'end-labeled

miR223 and miR223mut. Cell-free packaging of miR223 and miR223mut

measured as protected radioactive signal from ^{32}P labeled miR223 and

miR223mut. Reactions with or without membrane, cytosol, and 1% Triton

X-100, and incubated at 4 or 30 °C are indicated. For the samples

containing only cytosol plus membrane at 4 °C, only one-third of the

samples were loaded. Each sample was supplemented with 300mM urea

to reduce the background signal. (h.) Data quantification showed protected

fraction of miR223 and miR223mut as calculated from *in vitro* packaging

data shown in (g.)

Figure 2-figure supplement 1. Screening of exosomal sorting motif of

miR223.

EMSA competition assay to screen the exosomal sorting motif of miR223.

(a.-f.) EMSA competition assay using 1nM 5' fluorescently labeled miR223,

32nM purified YBX1 protein and unlabeled miR223 or miR223mutants.

Unlabeled miR223 or miR223mutants were titrated from 1nM to 1μM and

are given as the ratio of unlabeled miR223/labeled miR223 (wt and mutant).

Figure 3. Mitochondria contribute to miR223 enrichment into exosomes.

(a.) Immunoblot analysis of protein markers for different subcellular

fractions isolated from 293T cells. (b.) RT-qPCR analysis of miR223 fold

changes of different subcellular fractions isolated from 293T cells relative to

cell lysate. (c.) Immunoblot analysis of protein markers for mitoplasts

purified from 293T cells by Percoll gradient fractionation (MT: mitochondria;

MP: mitoplast). (d.) RT-analysis of COX1 mRNA, miR223 and U6 snRNA

fold changes for mitoplasts purified from 293T cells relative to cell lysate.

(e.) Immunoblot analysis of protein markers for immunoprecipitated mitochondria and osmotic shock generated mitoplasts. Mitochondria were purified from a 293T 3xHA-EGFP-OMP25 overexpressing cell line using anti-HA magnetic beads. Mitoplasts were purified following mitochondrial immunoprecipitation by osmotic shock, proteinase K and RNase treatment (IP-MT: immunoprecipitated mitochondria; IP-MP: immunoprecipitated mitoplasts). (f.) RT-analysis of COX1 mRNA, miR223, miR190 and U6 snRNA fold changes for immunoprecipitaed mitochondria and mitoplasts purified from the 293T 3xHA-EGFP-OMP25 overexpressing cell line. Data are plotted from 3 independent experiments and error bars represent standard deviations. (g.) RT-qPCR analysis of mitochondrial mRNA COX1 in U2OS cells expressing GFP-Parkin treated with or without CCCP. Data are plotted from 3 independent experiments and error bars represent standard deviations. (h.) Immunoblot analysis of mitochondrial marker Tim23 in U2OS cells expressing GFP-Parkin treated with or without CCCP. (i.) Schematic of exosome purification from mitochondria depleted GFP-Parkin expressing U2OS cells. (j.) RT-qPCR analysis of fold change of miR-223 and miR-190 in cells and purified exosomes from U2OS cells expressing GFP-Parkin which were treated with or without CCCP. Data are plotted from 3 independent experiments and error bars represent standard deviations.

Figure 3-figure supplement 1. miR223, but not miR190, enriched in mitochondria.

(a.) RT-qPCR analysis of miR190 fold changes in subcellular fractions isolated from 293T cells relative to cell lysate. Data are plotted from 3 independent experiments and error bars represent standard deviations. (b.)

Mitochondria immunoprecipitation. Mitochondria purified from 293T WT or
3xHA-EGFP-OMP25 overexpressing cell line using anti-HA magnetic
beads. Immunoblot detection of inner membrane marker COX IV, outer
membrane marker TOM20 and mitochondrial matrix protein citrate
synthase (CS) but not of the early endosome marker RAB5, lysosome
marker LAMP1, cytosol marker GAPDH and ER marker GRP78. (c.)
Purified mitochondria from (b.) were treated with 1% Triton X-100 or
freeze/thaw using liquid-nitrogen and the supernatant and pellet fractions
were collected after centrifugation. Immunoblot analysis of the
mitochondrial protein distribution of outer membrane protein TOM20, inner
membrane protein COX IV and matrix protein citrate synthase. (d.) and (e.)
RT-qPCR analysis of the distribution of COX1 mRNA and miR223 from (c.)
Data are plotted from 2 independent experiments and error bars represent
standard deviations.

Figure 3-figure supplement 2. Mitochondrial depletion did not change
exosome secretion.

(a.) CD63-Nluc was stably expressed in the cell lines expressing U2OS-
GFP-Parkin. Exosome numbers are measured by luminescence from the
conditioned medium of CD63-Nluc cells which were treated with or without
CCCP. Normalized exosome production from cells are shown.

Figure 4. YBAP1 directly and specifically binds miR223.

(a.) Strep II-YBX1 was overexpressed in HEK293T cells. Coomassie blue
detection of unknown band copurified with YBX1 from 293T cells. (b.)
Immunoblot identified unknown band was YBAP1. (c.) Tom22-mCherry
expressing U2OS was transfected with a YBAP1-GFP-expressing plasmid,

cultured for 12h and observed by confocal microscopy. Scale bar, 10 μm. (d.) Quantification of the fluorescence intensity of the different channels indicated by the solid white line of (c.). (e.) YBAP1 resides in mitochondria. Proteinase K protection assay for YBAP1 using purified mitochondria from 293T cells. Samples were treated with or without proteinase K (10 ug/ml) and or Triton X-100 (0.5%). Immunoblots for Tim23, Tom20 and YBAP1 are shown. (f.) Mitochondria were purified for immunoprecipitation with YBAP1 antibody. Immunoblot detection of YBAP1 and Tom20. (g.) RT-qPCR analysis of miR223 fold changes of YBAP1 IP samples. Data are plotted from 3 independent experiments and error bars represent standard deviations. (h-i.) EMSA assays using 1nM 5' fluorescently labeled miR223 or miR190. Purified YBAP1 was titrated from 500pM to 1μM. In gel fluorescence was detected. Quantification of (j.) shown the calculated Kd.

Figure 4-figure supplement 1. YBX1 and YBAP1 copurify as a complex from transfected SF9 cells.

(a.) YBAP1 purified from insect cells which overexpressed His-MBP-YBAP1. (b.) YBX1 and YBAP1 were copurified from insect cells which overexpressed His-MBP-YBX1 with untagged YBAP1.

Figure 4-figure supplement 2. YBAP1 does not share the same miR223-binding motif as YBX1.

(a.) EMSA assays using 1nM 5' fluorescently labeled miR223 WT or miR223mut or miR190 WT or miR190sort and purified YBAP1. Purified YBAP1 was titrated from 500pM to 1μM. In gel fluorescence was detected. (b.) Binding affinity curves as calculated by EMSA data from (a.)

Figure 5. YBAP1 sequesters miR223 which is released and secreted in YBAP1 KO cells

(a.) Schematic shows exosome and mitochondria purification from 293T WT cells and YBAP1 knock out cells for RT-qPCR analysis. (b.) Analysis of 293T WT and CRISPR/Cas9 genome-edited cells by immunoblot for YBAP1, YBX1 and mitochondrial markers (c.) RT-qPCR analysis of miR223 enrichment in mitochondria purified from 293T WT cells and YBAP1 KO cells relative to cell lysate. Data are plotted from 3 independent experiments and error bars represent standard deviations. (d.) RT-qPCR analysis of miR223 and miR190 fold change in cells, purified mitochondria and exosomes from 293T WT cells and YBAP1 KO cells. Data are plotted from 3 independent experiments and error bars represent standard deviations.

Figure 5-figure supplement 1. Knockout of YBAP1 did not change exosome secretion.

(a.) CD63-Nluc was stably expressed in the 293T WT and YBAP1-KO cell lines. Exosome production was measured by luminescence of CD63-Nluc in the conditioned medium of cells which were treated with or without CCCP. Normalized exosome production from 293T WT and YBAP1-KO cells are shown.

Figure 6. YBX1 puncta relocalize from mitochondria to endosomes.

(a.) YBX1 puncta on the mitochondria. U2OS cells were stained with anti-YBX1 and anti-YBAP1 antibodies and observed by confocal microscopy. The right panel shows enlarged regions of interest from the left panel.

Scale bar, 5 μm. (b.) The statistics are of the percentage of YBX1 puncta detected in proximity to mitochondria. n=30 cells. (c.) YBX1 puncta relocalize from mitochondria to endosomes. U2OS cells overexpressed YFP-YBX1, Rab5(Q79L)-mCherry and mito-BFP. Time-lapse images were acquired with a Zeiss LSM900 confocal microscope. Scale bar, 2 μm. (d.) The statistics are of YBX1 puncta shuttle events per cell. The data was represented as violin plots. N=34 cells.

Figure 7. Diagram representing a model of miR223 sorting from mitochondria into exosomes.

Stages in the transfer of miR223 from mitochondria. Cytosolic miR223 is enriched in mitochondria where it may be sequestered by a weak interaction with YBAP1. Cytoplasmic YBX1 interacts more tightly with miR223 which may drive the removal of miR223 from mitochondria. YBX1 in RNA granules may accumulate miR223 removed from mitochondria. YBX1 puncta may give rise to small particles carrying miR223 for uptake into endosomes and secretion in exosomes.

Figure 1 – source data. Uncropped gel images corresponding to Figure 1.

Figure 1 – figure supplement 2 – source data. Uncropped gel images corresponding to Figure 1 supplement 2.

Figure 2 – source data. Uncropped gel images corresponding to Figure 2.

Figure 2 – figure supplement 1 – source data. Uncropped gel images corresponding to Figure 2 supplement 1.

Figure 3 – source data. Uncropped immunoblot images corresponding to Figure 3.

Figure 3 – figure supplement 1 – source data. Uncropped immunoblot
images corresponding to Figure 3 supplement 1.

Figure 4 – source data. Uncropped immunoblot and gel images
corresponding to Figure 4.

Figure 4 – figure supplement 1 – source data. Uncropped gel images
corresponding to Figure 4 supplement 1.

Figure 4 – figure supplement 2 – source data. Uncropped gel images
corresponding to Figure 4 supplement 2.

Figure 5 – source data. Uncropped immunoblot images corresponding to
Figure 5.

1073

Figure 1. YBX1 directly and specifically binds miR223

Figure 1-figure supplement 1. Knockout of YBX1 did not change exosome secretion.

a.

Figure 1-figure supplement 2. Purified YBX1 full length protein and different truncations and mutation

a.

His-MBP-YBX1

b.

YBX1(1-51)
YBX1(52-129)
YBX1(130-324)

c.

YBX1(1-129)
YBX1(52-324)
YBX1(F85A)

Figure 2. miR223 sequence motif UCAGU binds YBX1

Figure 2-figure supplement 1. Screening exosomal sorting motif of miR223

Figure 3. Mitochondria contribute to miR223 enrichment into exosomes

Figure 3-figure supplement 1. miR223, but not miR190, enriched in mitochondria.

Figure 3-figure supplement 2. Mitochondrial depletion did not change exosome secretion.

a.

Figure 4. YBAP1 binds miR223 in the mitochondria and in vitro

[miRNA] = 1nM
Kd of miR223 = 173.2nM

Figure 4-figure supplement 1. YBX1 and YBAP1 copurify as a complex from transfected SF9 cells.

Figure 4-figure supplement 2. YBAP1 does not share the same motif as YBX1 that binds to miR223

Figure 5 . YBAP1 sequesters miR223 which is released and secreted in YBAP1 KO cells

Figure 5-figure supplement 1. Knockout of YBAP1 did not change exosome secretion.

a.

Figure 6. YBX1 puncta relocalize from mitochondria to endosomes

a.

YBX1
YBAP1

5μm

b.

c. YFP-YBX1 Rab5(Q79L)-mC mito-BFP

0s
3m48s
6m39s
2μm
9m30s
10m27s
28m28s

d.

Figure 7. Diagram representing a model of miR223 sorting from mitochondria into exosomes